Arvinas Stock News

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0

Arvinas (NASDAQ: ARVN ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Arvinas has an average price target of $114.0 with a high of $157.00 and a low of $91.00. Below is a summary of how these 4 analysts rated Arvinas over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … Full story available on Benzinga.com

Arvinas (NASDAQ: ARVN ) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Arvinas missed estimated earnings by 26.58%, reporting an EPS of $-1.0 versus … Full story available on Benzinga.com

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Arvinas press release (NASDAQ:ARVN): Q4 GAAP EPS of -$1.00 misses by $0.21.Revenue of $26.3M (+1095.5% Y/Y) beats by $11.22M.

NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

In last trading session, Arvinas Inc. (NASDAQ:ARVN) saw 0.66 million shares changing hands with its beta currently measuring 2.00. Company’s recent per share price level of $67.48 trading at $1.15 or 1.73% at ring of the bell on the day assigns it a market valuation of $3.59B. That closing price of ARVN’s stock is at … Arvinas Inc. (NASDAQ:ARVN) Projected To Shrink By -151.93% Or More Read More »

Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA50 rate and durable RECIST responses –

The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination of the omicron fears, and the anticip

The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination of the omicron fears, and the anticipation of the Fed raising rates to curb the surge of inflation. This has led to a growing concern about the possibility of a bear market this year. However, Goldman Sachs chief global equity strategist Peter Oppenheimer believes it''s time to buy. “Any further significant weakness at the index level should be seen as a buying opportunity, in our view, albeit with moderate upside through the year as a whole,” he recently wrote. Analysts at Goldman have set their sights on three stocks they believe will tower 70% or more this year: Arvinas Inc. (NASDAQ: ARVN ): Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.

Is it time to buy a basket of biotech stocks?

Arvinas Inc (NASDAQ: ARVN ) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. The data showed that bavdegalutamide continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant … Full story available on Benzinga.com